# DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:

> **NCT04884139** · PHASE4 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 554 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Dolutegravir/Lamivudine as a single pill
- **DRUG:** Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.

## Key facts

- **NCT ID:** NCT04884139
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2024-02-20
- **Final completion:** 2025-03-13
- **Target enrollment:** 554 (ACTUAL)
- **Last updated:** 2025-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04884139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04884139, "DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04884139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*